Synthetic Design Lab
United States
- San Francisco Bay Area
- 24/04/2025
- Unknown
- $20,000,000
A next-generation ADC company developing a novel SYNTHBODY therapeutic platform against a range of cancer types
- Industry Biotechnology Research
- Website https://www.syntheticdesignlab.com/
- LinkedIn https://www.linkedin.com/company/synthetic-design-lab-inc/
Related People
Daniel Chen, M.D. Ph.D.Founder
United States -
Burlingame, California
Author of The Cancer-Immunity Cycle (Immunity 2013) and the Cancer-Immune Set Point (Nature 2017) with Ira Mellman.
A pioneer in the field of Cancer Immunotherapy, emergence of PD-L1/PD-1 inhibitors and next generation therapies. Focused on the future of medicine and what's possible at the intersection between engineering, science and medicine.
Experienced drug developer (from pre-clinical through Phase I-IV), entrepreneur, executive- strong communicator and strategic leader with expertise in Oncology, Immunology, Large Molecule Engineering, Virology, Filings, Biomarkers and Building/Leading Organizations.
Sycamore Labs | $65,000,000 | (Mar 31, 2026)
Deccan AI | $25,000,000 | (Mar 31, 2026)
Stedi | $50,000,000 | (Mar 31, 2026)
OpenBox AI | $5,000,000 | (Mar 31, 2026)
Qodo | $70,000,000 | (Mar 31, 2026)
Starcloud | $170,000,000 | (Mar 31, 2026)
Valinor(1) | $25,000,000 | (Mar 31, 2026)
Mars Men | $27,500,000 | (Mar 31, 2026)
Scalvy | $13,900,000 | (Mar 27, 2026)
SIGMAS | $1,000,000 | (Mar 27, 2026)
CurrentClient | $1,250,000 | (Mar 27, 2026)
VITL | $7,500,000 | (Mar 27, 2026)